The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

FDA recently announced new safety requirements for DPD screening in cancer patients. Kristine Ashcraft, founder and CEO of ...

Kepler Capital analyst Nicolas Pauillac maintained a Buy rating on MedinCell SA (MEDCL – Research Report) on February 26 and set a price ...